Podcasts about life sciences

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jeanne Taylor Hecht, Chief Executive Officer and Chairwoman at Lexitas. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeanne, covering: How Jeanne's various roles have equipped her to become a more rounded CEO and board member. How a stint in Asia led Jeanne to develop her strategy playbook, including the importance of the client's voice. Jeanne's journey, taking on eight different boards and becoming a serial investor and advisor... and how that did not happen by accident. She said that having a strong relationship with a PE firm and missing the hands-on, day-to-day role of being a CEO led her back to the hot seat. Understanding why has being a specialist ophthalmology CRO given Lexitas traction with small to medium biotechs, and what is the future in store for CROS? Jeanne's industry career spanned over twenty-five years as a Board member and Chief Executive Officer of multiple companies, including CEO at Ora and Senior Executive at Median Technologies, IQVIA, Decision Biomarkers, and the UNC Oncology Protocol Office. Jeanne also launched and expanded a Life Sciences consulting practice that supported companies with sales, marketing, and market growth strategies and advisory and board work. She is primarily motivated by helping to bring relief to patients.  Jeanne is an active Advisory Board Member for the University of North Carolina Chapel Hill Kenan-Flagler's Business School and Lecturer at the business school. She contributed to the creation of Wake Forest University's master's in clinical research program and remains an active industry advisor to the school. She holds a Bachelor of Science from the University of Michigan and a Master of Business Administration from the university's Ross School of Business. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!  Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Santosh Kaveti is the CEO and Founder of ProArch. He has over 18 years of experience as a technologist, entrepreneur, investor, and advisor. Santosh's vision and leadership have propelled ProArch to become a dominant force in key industry verticals, such as Energy, Healthcare & Lifesciences, and Manufacturing, where he leverages his expertise in manufacturing process improvement, mentoring, and consulting00:00 Intro03:48 Protect what matters the most12:32 Talking to the client. What is worth protecting24:27 Proarch29:30 The Cultural fit with acquisition 36:40 Disaster Recovery39:50 What do you think AI is going to do?43:55 Im too small to get attacked--------------------------------------------------------------To learn more about Santosh visit https://www.linkedin.com/in/santoshkaveti/To learn more about Dark Rhiino Security visit https://www.darkrhiinosecurity.com--------------------------------------------------------------

Santosh Kaveti is the CEO and Founder of ProArch. He has over 18 years of experience as a technologist, entrepreneur, investor, and advisor. Santosh's vision and leadership have propelled ProArch to become a dominant force in key industry verticals, such as Energy, Healthcare & Lifesciences, and Manufacturing, where he leverages his expertise in manufacturing process improvement, mentoring, and consulting00:00 Intro03:48 Protect what matters the most12:32 Talking to the client. What is worth protecting24:27 Proarch29:30 The Cultural fit with acquisition 36:40 Disaster Recovery39:50 What do you think AI is going to do?43:55 Im too small to get attacked--------------------------------------------------------------To learn more about Santosh visit https://www.linkedin.com/in/santoshkaveti/To learn more about Dark Rhiino Security visit https://www.darkrhiinosecurity.com--------------------------------------------------------------

This is a free preview of a paid episode. To hear more, visit www.louiseperry.co.ukMy guest today is Marco Del Giudice, Associate Professor in the Department of Life Sciences at the University of Trieste. We spoke about one of Marco's key research interests: evolutionary psychopathology. That is, how our evolutionary history influences mental illness. We spoke about how gender differences in personality influence psychopathology, part…

Today's guest is Annabel Romero, Specialist Leader focusing on AI for Drug Discovery at Deloitte and a structural biologist by training. Deloitte is a global consulting firm known for its work in digital transformation, data strategy, and AI adoption across regulated industries. Annabel joins Emerj Editorial Director Matthew DeMello to explore how AI systems are being designed to think more like scientists—particularly in protein modeling and life sciences research. She shares how tools like AlphaFold and large language models are accelerating drug targeting, predicting allergen cross-reactivity, and translating learnings from human biology to agricultural innovation. This episode is sponsored by Deloitte. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

In this episode of Tiny Show and Tell Us, we talk about why the FDA recently banned Red Dye No. 3 and how concerned people should be about its use in food. Then we cover icy winter roads and the fascinating science behind clearing them and taking a more sustainable approach that won't hurt the environment.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Keith Willis joins the Lounge to discuss his early years of Military Service as an officer in the Gulf War and how it launched him into his Leadership journey. Founder of Core Management Training Keith gives great insight on the core competencies of Leadership.

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Yunke Xiang, Global Head of Data Science for Manufacturing, Supply Chain, and Quality at Sanofi. Yunke joins Emerj Editorial Director Matthew DeMello to discuss the challenges that slow AI adoption in life sciences manufacturing, highlighting how fragmented data systems and legacy infrastructure create hurdles for AI initiatives. In this episode, Yunke explains how years of acquisitions and siloed data have made building a cohesive data foundation difficult, impacting AI's potential in manufacturing and supply chain optimization. Yunke shares Sanofi's approach to balancing build versus buy decisions for AI solutions and the critical role leadership plays in fostering an environment where data science can thrive. Yunke also reflects on the evolving landscape of AI in pharma manufacturing and the importance of strong governance and collaboration for successful implementation. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

We are surrounded by bold claims and quick fixes for ‘boosting' our immune health. But one thing the science is clear on is that everyone's immune system is unique – what is good for one person may not work well for another. So how do we separate the bogus claims from the useful advice? Head of Life Sciences and Professor of Immunology at Imperial College, Daniel Davis, helps us sort the facts from the fiction. From the genetics of immune health to the myth of Vitamin C, from evidence-backed studies on chronic stress to the gaps in knowledge on sleep and microbiome health, Daniel reveals what scientists do know for certain—and what still needs more answers—to help us make informed choices for ourselves. Learn more about your ad choices. Visit podcastchoices.com/adchoices

n this episode of Psychedelics Today, kicking of Psychedelic Science 2025 week in Denver, we sit down with Jonathan Dicksinson, Chief Executive Officer, and Trevor Millar, Chief Operations Officer of Ambio Life Sciences – one of the world's leading ibogaine clinics – to explore the potential of ibogaine for addiction, neuroregeneration, and how ethics, honoring experience, and sustainability will be key to delivering ibogaine at scale.  Trevor shares his early work supporting marginalized populations in Vancouver's Downtown Eastside, which led to the founding of Liberty Root, one of Canada's first ibogaine clinics. Jonathan reflects on his apprenticeship in Mexican clinics, years of international advocacy with the Global Ibogaine Therapy Alliance, and drafting the first set of clinical guidelines for ibogaine detoxification. Together with paramedic and ibogaine safety protocols expert Jose Inzunza, they co-founded Ambio in Tijuana in 2021. They discuss: The unique safety standards Ambio has pioneered – including industry-wide clinical protocols and magnesium therapy to mitigate cardiac risk. Their scale: over 3,000 patients treated, with 100+ clients per month across five dedicated houses in Baja California. Ambio's groundbreaking neuroregenerative program for Parkinson's, MS, and traumatic brain injury – which has already drawn patients like Brett Favre and Clay Walker. How ibogaine appears to drive profound physiological change – including evidence of TBI reversal as shown in Stanford's 2024 study on Special Forces veterans. Why ibogaine isn't just a molecule – it opens a long-lasting “critical period” of neuroplasticity that must be supported with preparation, integration, and holistic care. The deeper story of sourcing: through his company Terragnosis, Jonathan is the only person with a legal export license for Tabernanthe iboga from Gabon, and Ambio is setting a precedent for reciprocal and ethical global supply chains. Their cautionary perspective on Texas' $50M push toward ibogaine clinical trials – and why the traditional “one drug, one indication” model misses the complexity and promise of psychedelic healing. They also make a compelling case that Ambio is already modeling what the future of psychedelic care should look like – not a single drug in a sterile clinical setting, but a comprehensive, integrated protocol combining preparation, medical oversight, and deep integration. “Start with the end in mind,” Trevor urges – Ambio isn't just part of the movement; it's the blueprint for how ibogaine could be delivered worldwide. Links: Ambio Website: https://ambio.life/ Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis (Frontiers in Immunology, Feb 2025) Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Nature Medicine, Jan 2024) Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion (Frontiers in Pain Research, Aug 2023) Novel treatment of opioid use disorder using ibogaine and iboga in two adults (Journal of Psychedelic Studies, Jan 2020) Clinical Guidelines for Ibogaine-Assisted Detoxification Ambio Life Sciences Launches World's First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions Bios:  Jonathan Dickinson is the Chief Executive Officer and Co-Founder of Ambio Life Sciences. One of the world's leading experts on ibogaine, Jonathan brings over 15 years of experience in clinical care, traditional practice, and psychedelic research to his leadership at Ambio. A Mexico-licensed psychologist and former Executive Director of the Global Ibogaine Therapy Alliance, he authored the field's foundational safety guidelines and has published widely on ibogaine's therapeutic, cultural, and ecological significance. He holds the only active export license for Tabernanthe iboga root, led the first Nagoya-compliant export from Gabon, and was initiated into the Dissoumba/Fang tradition of Bwiti in 2014 and the Missoko tradition in 2022. He has co-authored peer-reviewed research on ibogaine's potential for trauma, TBI, pain, MS, and Parkinson's. At Ambio, he leads strategy, research, and innovation – advancing a globally scalable model of care that bridges tradition, science, and integrity. Trevor Millar is the Chief Operating Officer and Co-Founder of Ambio Life Sciences. A social entrepreneur and pioneer in ibogaine advocacy and treatment, Trevor brings over a decade of experience supporting individuals through addiction recovery, trauma healing, and post-treatment integration. His background includes co-founding the Canadian Psychedelic Association and serving as Chair of the Board for MAPS Canada. He has co-authored peer-reviewed research on ibogaine's applications for trauma, TBI, and opioid use disorder, and has been featured in award-winning documentaries including DOSED and In Waves and War. Grounded in personal experience and guided by a philosophical approach to healing, Trevor is helping shape a new model for ethical, integrative psychedelic care on a global scale. At Ambio, Trevor leads operations, strategic partnerships, and client experience – bridging clinical care with systems design, education, and public advocacy.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Tom Wells, Director of Life Sciences at 4C Associates, reveals why -- and how -- smart procurement practices can make or break emerging biotech companies during critical growth stages. Tom shares insights into procurement tools and strategies that can deliver breakthrough solutions, how poor procurement practices can damage investor confidence, and why thinking about procurement as the front end of demand flow, not the back end of supply chain, can help drug developers avoid costly mistakes. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode, Duane Mancini is joined by Harrison Lands, Director of Translational Sciences at UPMC Enterprises. Harrison brings a unique perspective, shaped by his background as a physician, MBA, consultant, and now investor. We delve into the workings of UPMC Enterprises, exploring their investment thesis – the who, what, how much, when, and how their fund operates. Harrison also sheds light on the powerful advantages of UPMC's payer/provider integrated medical system and its impact on fostering innovation. The conversation touches on the vibrant Pittsburgh life science community, Harrison's time at the University of Virginia, and insights from CvilleBioHub. Tune in to understand how a major integrated health system strategically invests and drives translational science forward.Harrison Lands LinkedInUPMC Enterprises WebsiteDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedIn

睽違半年Happy Hour總算更新啦！這次若晴跟Angel來聊聊最近剛從研討會回來的一些見聞和心得，非常適合搭配上一集新手村005一起收聽！當然我們也不忘Happy Hour的慣例，跟大家分享了一則近期非常振奮人心的客製化基因療法突破的新聞。等待Happy Hour已久的聽眾趕緊收聽吧！ 節目內容： 跟大家更新一下近況 客製化基因療法大突破 芝加哥三腳貓4/6小聚 AACR開幕式小花絮 跟同事學了poster session的搜集資訊的招數 小廢物拿好拿滿還有免費專業大頭照 NIH fellowship小會議見聞 會議結識新朋友的喜悅 -- Hosting provided by SoundOn

Le "paradoxe français" désigne une observation intrigante : les Français, malgré une alimentation riche en graisses saturées (fromages, beurre, charcuterie), ont un taux relativement bas de maladies cardiovasculaires, en comparaison avec d'autres pays occidentaux comme les États-Unis. Cette contradiction apparente a été mise sous les projecteurs aux États-Unis le 17 novembre 1991, lors d'un épisode de l'émission très populaire 60 Minutes diffusée sur CBS. Le segment, intitulé "The French Paradox", présentait l'idée que la consommation régulière de vin rouge par les Français pourrait être la clé de leur bonne santé cardiovasculaire.L'impact de cette émission a été immédiat : selon les données du Wine Market Council, les ventes de vin rouge ont augmenté de 44 % aux États-Unis dans les mois qui ont suivi. En 1992, le vin rouge représentait environ 70 % des nouvelles ventes de vin sur le marché américain, contre seulement 50 % l'année précédente. Certaines marques françaises comme Château Lafite Rothschild ont vu leur popularité exploser, et les importations de vin français ont fortement progressé.Sur le plan scientifique, l'un des principaux promoteurs de ce concept était le chercheur Serge Renaud de l'INSERM à Lyon. Dans un article publié en 1992 dans The Lancet, il avance que la consommation modérée de vin rouge – un à deux verres par jour – pourrait réduire le risque de maladies coronariennes de 40 %. Le vin rouge contient en effet des polyphénols, dont le plus connu est le resvératrol, un antioxydant présent dans la peau du raisin. Des études comme celle de J.P. Fremont (1999, Life Sciences) ont suggéré que le resvératrol inhibe l'agrégation des plaquettes et protège les vaisseaux sanguins.Le "paradoxe français" est alors devenu un argument marketing massif. L'industrie vinicole, en France comme aux États-Unis, s'en est emparée pour promouvoir le vin rouge comme un produit "santé". Cette stratégie a contribué à modifier l'image du vin outre-Atlantique, le faisant passer d'un produit de luxe européen à un choix de consommation perçu comme bénéfique.Cependant, cette idée a été nuancée fortement depuis. Aujourd'hui on sait que scientifiquement, la consommation modérée d'alcool n'est pas totalement sans risque, même à faibles doses.Citons l'étude de référence : The Lancet, 2018 – Global Burden of Disease StudyIl s'agit de l'une des études les plus vastes jamais réalisées sur le sujet, couvrant plus de 28 millions de personnes dans 195 pays. Elle conclut que le niveau de consommation d'alcool le plus sûr est zéro. Même à faibles doses, l'alcool augmente les risques de certains cancers, de maladies cardiovasculaires et de blessures.Cette étude remet donc totalement en cause l'idée selon laquelle une consommation modérée, comme un verre de vin par jour, pourrait être bénéfique pour la santé. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Meet Dr. Bo Wen, a staff research scientist, AGI specialist, cloud architect, and tech lead in digital health at IBM. He's joining us to discuss his perspective on the rapid evolution of AI – and what it could mean for the future of human communication… With deep expertise in generative AI, human-AI interaction design, data orchestration, and computational analysis, Dr. Wen is pushing the boundaries of how we understand and apply large language models. His interdisciplinary background blends digital health, cognitive science, computational psychiatry, and physics, offering a rare and powerful lens on emerging AI systems. Since joining IBM in 2016, Dr. Wen has played a key role in the company's Healthcare and Life Sciences division, contributing to innovative projects involving wearables, IoT, and AI-driven health solutions. Prior to IBM, he earned his Ph.D. in Physics from the City University of New York and enjoyed a successful career as an experimental physicist. In this conversation, we explore: How Dr. Wen foresaw the AI breakthrough nearly a decade ago The implications of AGI for communication, reasoning, and human-AI collaboration How large language models work. What AI needs to understand to predict words in sentences.  Want to dive deeper into Dr. Wen's work? Learn more here! Episode also available on Apple Podcasts: http://apple.co/30PvU9C

Breaking Free from Healthcare's Escape Room: Tom Lawry on AI Strategy and Systemic Hope Tom Lawry, Microsoft's former Director for AI in Health and Life Sciences and author of the new book Health Care Nation, joins us to discuss moving beyond healthcare fatalism toward actionable reform. Named one of 20 people transforming healthcare through practical AI applications, Lawry reveals how leaders can escape the industry's design flaws through strategic technology deployment and "micro-dosing hope." Essential listening for executives ready to move from critique to implementation. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

In this thoughtful conversation, we explore the transformative role of AI in healthcare. From over a thousand FDA-approved AI-enabled medical devices to breakthroughs in medical imaging, the discussion highlights the importance of trust, transparency, and bias mitigation. Join Tracy Ring, Chief Data Officer and Global Generative AI Lead for Life Sciences; Tom Kawalec, Managing Director for Life Sciences Practice at Accenture; and Shaye Mandle, Executive Director of Digital Health Tech at AdvaMed, as they delve into AI's future in personalized care and its potential to reduce healthcare costs.

Send us a textDaniel Tabb brings over 15 years of experience in the insurance industry, specializing in working with Life Science companies ranging from pre-seed startups to publicly traded corporations. As a leader of the Life Science Practice at Houchens Insurance Group, Daniel possesses a deep understanding of the unique risks and challenges faced by life science companies in today's dynamic environment.00:00 Introduction to Life Science Success Podcast00:29 Meet Daniel Tabb: Life Sciences Insurance Expert01:26 Daniel's Journey into the Insurance Industry03:32 Specializing in Life Sciences05:09 Key Career Transition Points12:06 Understanding Life Sciences Insurance15:49 Unique Risks and Challenges in Life Sciences18:23 Innovative Projects and Future of Insurance24:17 Leadership and Personal Insights33:49 Conclusion and Final Thoughts

Send us a textIn this episode of the Life Science Success Podcast my guest is Holley Miller, a category designer and commercial growth expert who helps life sciences companies drive reliable revenue and build market dominance through her innovative strategies at Grey Matter Marketing. With 30 years of experience in global marketing and product management, Holley transforms companies by changing market behaviors and creating category leadership.00:00 Introduction to Life Science Success Podcast00:35 Meet Holley Miller: Category Designer and Commercial Growth Expert01:35 Holley's Journey into Life Sciences02:41 Transition from Tobacco to Medical Devices05:15 Understanding Category Design08:58 Examples of Successful Category Design12:05 Founding Grey Matter Marketing18:04 Challenges in Life Sciences Marketing23:14 Strategies for Effective Market Adoption26:46 The Importance of Problem Marketing29:12 Innovative Solutions in Spinal Surgery31:33 Frameworks for Understanding Company Vision35:17 Challenges and Overcoming Obstacles37:53 Evolution and Lessons from Grey Matter40:35 Focus Areas and Client Selection43:27 Success Stories and Impact47:29 Leadership Advice and Inspirations48:44 Concerns and Future of Healthcare Technology50:12 Generative AI and Future Prospects54:25 Conclusion and Contact Information

This week, Heather and Matthew are joined by their colleague Bryan Baysinger, Maynard Nexsen attorney and leader of the firm's Intellectual Property practice group. We dive into the evolving challenges life sciences companies face in protecting intellectual property in a time when artificial intelligence is reshaping research and innovation. From securing patents and trade secrets to navigating international competition, Bryan offers practical guidance for companies looking to strengthen their IP portfolios. Tune in for insights on the intersection of IP, AI, and the future of the life sciences industry

AI transforms how healthcare data is structured, analyzed and applied to clinical decision-making in life sciences. Discover how leading experts harness artificial intelligence to streamline clinical workflows, enhance data quality and accelerate actionable insights for healthcare providers and diagnostic organizations. Mika Newton, CEO of xCures, and Rajiv Haravu, SVP of Product Management at IMO Health, break down practical frameworks for applying AI to complex patient records, from medical coding to interoperability strategies. Understand how AI-driven tools empower healthcare teams to navigate vast medical datasets, improve patient care pathways and support value-based care delivery.

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Deloitte Digital leaders as they delve into the current state of the industry and discuss the future of customer engagement for pharmaceutical companies. Learn what leaders should be considering today and the key impacts that will come from these decisions in the months and years to come. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

As summer begins, students across the country will be shedding the carefree summers of childhood in exchange for work experience and college credits in the form of internships. But beyond just completing a graduation requirement, research shows that internships create positive and crucially important outcomes for students as they move into the workforce and develop skills and interests, build networks and solidify career goals. . On this episode of Moving Forward, Giving Back, we begin with a quick introduction to LSC Philadelphia's new executive director Jennifer Parrado by our CEO Sarah MacDonald. Then Jenn talks with three alums of LSC's summer internship program, Project Onramp. Project Onramp connects students to early work opportunities to explore pathways in our industry. Serena Burkinshaw, Fadi Shamaan, and Alain Santo Domingo discuss their internship experiences through Project Onramp, what they learned, tips for future participants, as well as the importance of stepping out of your comfort zone as you enter the workforce. It's a timely and informative conversation that we can all benefit from at this time of year!Learn more about Life Science Cares at lifesciencecares.org and Project Onramp at projectonramp.us. 

In a groundbreaking development for the digital health world, Eli Lilly, one of the world's largest pharmaceutical companies, has filed lawsuits against a growing number of telehealth companies over the sale of compounded drugs Mounjaro and Zepbound, two popular GLP-1 medications. Nawa Lodin, Associate, Wilson Sonsini Goodrich & Rosati, and Lauren Petrin, Associate, Wiley Rein, discuss the background of compounding and when it is allowed under FDA regulations; the legal and regulatory issues at play in Eli Lilly's lawsuits, including issues related to the corporate practice of medicine and FDA regulations; and key compliance considerations. Watch this episode: https://www.youtube.com/watch?v=XstaVQGtY24AHLA's Health Law Daily Podcast Is Here! AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this new podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.

For decades, multinational corporations have used sophisticated strategies to shift profits away from where they do business. As a result, countries around the world lose an estimated US$500 billion annually in unpaid taxes, with developing nations hit particularly hard.In the first episode of The 15% solution, we explore how companies have exploited loopholes in the global tax system. We speak to Annette Alstadsæter, director of the Centre for Tax Research at the Norwegian University of Life Sciences, and Tarcisio Diniz Magalhaes, a professor of tax law at the University of Antwerp in Belgium. In 2021, after years of international negotiations, the Organisation for Economic Co-operation and Development unveiled a global tax deal designed to address tax avoidance through a minimum corporate tax rate of 15%. But will this new framework actually work? And what happens when major economies refuse to participate? The 15% solution explores why a new global tax regime is needed, whether it can fix a broken system, and what's at stake if it fails.This episode of The Conversation Weekly was written and produced by Mend Mariwany. Gemma Ware is the executive producer. Mixing and sound design by Eloise Stevens and theme music by Neeta Sarl. Sound design and mixing by Eloise Stevens and theme music by Neeta Sarl. Read the full credits for this episode and sign up here for a free daily newsletter from The Conversation.If you like the show, please consider donating to The Conversation, an independent, not-for-profit news organisation. Donation

Welcome to Automating Quality, the life sciences–focused show that bridges the gap between automation and quality management. In today's episode, Ed and Philippe explore how quality can bring added value to a company and discuss strategies to shift organizational mindsets to unlock the full potential of quality departments. Ed Siurek brings over 30 years of hands-on experience in applying quality standards and ensuring regulatory compliance in the pharmaceutical and medical device industries. He has trained hundreds of quality professionals and is a strong advocate for positioning quality as a driver of business value. After 13 years with a consulting firm, Ed recently transitioned full-time to his own company, ES3 Solutions Inc.   Key Takeaways 00:53 – Introducing Ed Siurek 02:20 – Why is quality sometimes perceived as a cost? 05:50 – Always remember: our products are ultimately used on people 09:02 – “If it's not written down, it didn't happen” 10:20 – Use your risk report — don't let it collect dust 13:20 – How are regulatory bodies viewed in the industry today? 21:15 – What is the role of a quality plan?   Contact us at solabs-podcast@solabs.com for questions or suggestions. Contact Ed Siurek at Always improving ES3 Solutions

In this episode of Tiny Show and Tell Us, we talk about what dark energy and dark matter are made out of and how knowing more could upend our understanding of the Big Bang. Then we cover microchimeric cells — cells transferred between baby and mom — and how new research in mice shows that fetal cells that took residency in mom from a first pregnancy are replaced by new fetal cells of a second pregnancy.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Johns Creek: Number One Best U.S. City to Live In, with Mayor John Bradberry and Brian Lynam, Boston Scientific (GNFCC 400 Insider, Episode 107) Join GNFCC CEO Kali Boatright in this episode of the GNFCC 400 Insider podcast as she chats with Johns Creek Mayor John Bradberry and Boston Scientific Senior Director Brian Lynam, discussing […] The post Johns Creek: Number One Best U.S. City to Live In, with Mayor John Bradberry and Brian Lynam, Boston Scientific appeared first on Business RadioX ®.

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Tune in as Glenn Hunzinger, PwC's Health Industries Leader, and Phil Scalfani, PwC's Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration's executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader drug supply chain, and share perspectives on how organizations can navigate the uncertainty ahead.  Discussion Highlights: The MFN executive order is a bold attempt to lower U.S. drug prices by benchmarking them against the lowest prices paid in other high-income countriesPharma companies may be forced to rethink global pricing strategies, balancing U.S. price cuts with potential increases or market exits abroadA proposed shift to direct-to-consumer drug access could disrupt traditional roles for pharmacies, distributors, and pharmacy benefit managers (PBMs)Companies are preparing for significant uncertainty by reassessing deals, modeling financial impacts, and closely monitoring upcoming rulemaking and potential legal developmentsSpeakers:Glenn Hunzinger, Health Industries Leader, PwCPhilip Sclafani, Partner, Pharma & Life Sciences, PwCLinked materials:Most Favored Nation prescription drug pricing Executive OrderFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

In science, the Blavatnik Award for Young Scientists of 2025 were announced this week. The prestigious award went to three early-career scientists among 36 nominees and also includes a 100,000 dollar grant for each one for their groundbreaking research in three fields – Life Sciences, Chemical Sciences and Physical Sciences & Engineering. We spoke with one of the recipients, Dr. Benjamin Palmer, Assistant Professor of Chemistry at Ben-Gurion University of the Negev. He is being recognized for his pioneering research on how organisms form crystals. (photo: courtesy) See omnystudio.com/listener for privacy information.

In bioprocess development, the ability to rapidly screen conditions and predict scale-up performance can mean the difference between a successful therapy launch and costly delays. Today's Smart Biotech Scientist episode features Tom Valentin from CSEM, who's pioneering revolutionary approaches to miniaturized perfusion systems that could transform how we develop biologics.Tom is a group leader at CSEM for Automated Sample Handling within the Life Sciences and Industry 4.0 business unit. As a mechanical and biomedical engineer, he brings a unique cross-disciplinary perspective to solving bioprocessing's most challenging miniaturization problems.What makes this conversation essential listening:96-deep-well plates are revolutionizing perfusion development: Tom reveals how CSEM's innovative fluidic lids enable continuous medium exchange in 300-microliter volumes, potentially allowing up to 96 parallel perfusion experiments with automated liquid handlers and shaker incubatorsThree critical barriers still need solving: Despite the promise, Tom identifies the key technical challenges that must be overcome: ultra-low flow rate liquid handling (imagine exchanging 300 μL over 24 hours), effective cell retention in miniaturized systems, and cost-effective real-time biomonitoring that fits within well plate constraintsThe future of process development is automated and intelligent: From pressure-over-liquid systems to advanced sensor integration, Tom outlines how companies can achieve near-autonomous perfusion screening—but warns that current sensing limitations mean viable cell density monitoring remains the "holy grail" of small-scale perfusionThis isn't just about smaller equipment—it's about fundamentally changing how we approach process development. If you're working in cell culture optimization, process scale-up, or bioprocess automation, Tom's insights reveal both the tremendous opportunities and practical realities of implementing next-generation perfusion systems.For biotech professionals, staying ahead means embracing these high-throughput, data-rich models, allowing smarter, faster, and more predictive process development for the therapies of tomorrow.Discover how bioprocessing is evolving - from high-throughput screening to digital twins and continuous manufacturing- in these expert-led episodes.Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes EverythingEpisodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 73-74: Bead-Based Assays: The Power of High-Throughput Screening with Sebastian GiehringConnect with Tom Valentin:LinkedIn: www.linkedin.com/in/tom-valentin-5bb9091bWebsite: www.csem.ch/enEmail: thomas.valentin@csem.chNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/Support the show

We welcome Karla Childers to AI Uncovered. Karla is a long-standing leader in bioethics and data transparency in the pharmaceutical industry. As part of the Office of the Chief Medical Officer at Johnson & Johnson, she brings deep expertise in navigating the ethical implications of emerging technologies, especially artificial intelligence, in medicine and drug development.In this episode, Tim and Karla explore the intersection of AI, bioethics and patient-centered development. They discuss how existing ethical frameworks are being challenged by the rise of generative AI and why maintaining human oversight is critical—especially in high-context areas like clinical trial design, consent and medical communications. Karla also shares her views on the future of data privacy, the complexity of patient agency and how to avoid losing trust in the race for efficiency.Karla is a strong advocate for using innovation responsibly. From her work with internal bioethics committees to her perspective on evolving regulatory expectations, she offers bold insights into how the industry can modernize without compromising ethics or equity.Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries. With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product.

What happens when cutting-edge science meets compassion? In this episode of Sounds of Science, host Mary Parker sits down with two pioneers reshaping the future of research: Elizabeth Nunamaker, Executive Director of Global Animal Welfare and Training at Charles River, and Dr. Megan LaFollette, Executive Director of the 3Rs Collaborative. From digital biomarkers to environmental health monitoring, they reveal how innovation and collaboration are redefining what's possible in animal welfare — and raising the bar for ethical, high-quality research. Tune in to explore the tools, strategies, and bold ideas driving meaningful change across the scientific community.Show NotesAdvancing Alternatives | Charles RiverEvolving Animal Welfare: Science, Ethics, and Innovation | Sounds of Science Can You Practice High-quality Science and 3Rs? | Eureka BlogAnimals in Research | Charles RiverResearch Models & Services | Charles River

We love to hear from our listeners. Send us a message. On this week's episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for treating depression, anxiety, and other mental health disorders. Internal drug development efforts at atai are focused on short-duration psychedelics that can work within existing healthcare infrastructure, with the potential to transform the treatment of mental health disorders. Rao also talks about atai's hub and spoke model for investing in other psychedelic companies, what MAPS/Lykos Therapeutics got wrong in the run-up to FDA's review of Lykos's MDMA candidate for PTSD, and whether psychedelic therapies need the "trip" to catalyze network disruption and neuroplasticity in the brain. This episode of the Business of Biotech is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Managing editor Anna Townshend spoke with two team members at BioMADE, which is one of nine different Manufacturing Innovation Institutes started by the Department of Defense. This particular group is focused on building the U.S. bioindustrial economy. There are many companies and scientists doing great work using chemical waste products to create new products that we often lack a domestic supply chain for, and the organization is also focused on commercializing and scaling the technology needed to do this work and the workforce to support the industry. Jill Zullo, executive vice president and chief operating officer at BioMADE, has a long career supporting sustainable products and focused on new bioindustrial markets. Most recently, she worked at Cargill, as interim president & CEO of NatureWorks, a Cargill joint venture focused on biomanufacturing development to replace fossil fuel-based materials. Tim Dobbs, data architect for BioMADE's data science team, is a chemical engineer with a degree from the University of Connectivity and a master's degree in Life Sciences. At BioMADE, he designs, models and deploys data models to BioMADE's member organizations. He and the technology team at BioMADE provide the unified computational infrastructure for bioproduction-centered collaboration across industry, academia and government.

Geoff Nelson is the Vice President of Technical Solutions at SafetyChain. SafetyChain is a digital plant management platform for process manufacturers trusted by more than 2,000 facilities to improve plant-wide performance. It unifies production and quality teams with data and insights, tools, and delivers real-time operational visibility and control by eliminating paper and point solutions. Geoff has been with SafetyChain for over 11 years. Prior to taking on his current role, Geoff held senior leadership roles in engineering, software development and product development. The Industry 4.0 Podcast with Grantek delivers a look into the world of manufacturing, with a focus on stories and trends that lead to better solutions.   Our guests will share tips and outcomes that will help improve your productivity. You will hear from leading providers of Industrial Control System hardware and software, Grantek experts and leaders at best-in-class industry associations that serve Life Sciences and Food & Beverage manufactures.  

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textIn this episode of the Life Science Success Podcast my guest is Elizabeth Chabe, the founder of High Touch Group (HTG) and an expert in science marketing with a distinguished background spanning research universities, national labs, and technology transfer offices. Elizabeth brings a wealth of experience in guiding researchers through technology commercialization and providing data-driven marketing strategies for life sciences and diagnostics companies, and is also the author of "The Giant's Ladder: The Science Professional's Blueprint for Marketing Success."00:00 Introduction to Life Science Success Podcast00:29 Meet Elizabeth Chabe: Entrepreneurial Journey01:12 Early Business Ventures and Education03:59 Transition to Life Sciences and Marketing06:41 Challenges and Insights from Academia11:39 Founding High Touch Group14:55 High Touch Group Services and Success Metrics19:34 The Giants Ladder: A Book for Founders23:10 Commercializing Innovations: Strategies and Pitfalls23:56 Challenges in Creating Market Demand25:26 Common Pitfalls in Product Development25:56 Importance of Audience Research27:05 Y Combinator's Critique on Entrepreneurial Approaches27:47 The Role of Multi-Skilled Teams in Marketing29:55 Successful Marketing Campaigns34:32 Innovative Trends in Life Sciences Marketing38:00 Leadership Advice and Team Collaboration42:54 Concerns About Federal Funding Cuts46:33 Excitement for Future Diagnostic Products

In this special episode of Trending Health, Mindy McGrath and Karen Baldry explore how recent changes across the U.S. federal health agencies and policies from the new administration are impacting the life sciences and biotech industry compounding with other pressures like the IRA, tariffs, and budget constraints. From launch delays at the FDA to supply chain strain and evolving patient access challenges, Mindy and Karen provide strategic considerations for commercial leaders as they navigate these shifts and uncertainties.   To learn more about how we can help your team with scenario planning and navigating these strategic decisions, reach out to . Check out our recent insights for more information: U.S. Federal Health Agency Layoffs Pose Strategic Risk and Disruption to Life Sciences & The Case for Strategic Transformation: An Executive Conversation with Vynamic's Leaders    Podcast Tags: healthcare, life sciences, public health, life sciences trends, healthcare strategy, health innovation    Panel – Mindy McGrath, Karen Baldry  Research & Production – Mindy McGrath, Karen Baldry, Everly Petruzzelli  Recording & Editing – Mike Liberto, Rachel Skonecki   

Efficiency is a top benefit of AI, but how do you create value beyond that? Aditya Kudumala, Deloitte's Global Life Sciences & Health care AI lead, explains how the “string of pearls” methodology turns AI into a strategic lever for broader transformation.

Today's guest is Daniel Ferrante, AI Leader in R&D and Data Strategy at Deloitte. Daniel joins Emerj CEO and Head of Research Daniel Faggella on today's show to delve into the intersection of AI, data strategy, and research and development across industries such as agriculture, life sciences, and materials science. Ferrante breaks down the core challenges organizations face in harnessing data to unlock AI's potential and drive efficiencies in R&D processes. Ferrante also emphasizes the importance of contextualizing data through a multimodal framework — Deloitte's Atlas — to bridge gaps between disparate datasets and ontologies. He outlines how AI models, including large language models (LLMs), can be leveraged to label and map complex data landscapes. This episode is sponsored by Deloitte. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com Organizations must recognize that AI risk management is a shared responsibility across the entire organization, not solely confined to cybersecurity, legal, or compliance teams.  In this episode, Michael Crowthers, Managing Director of Life Sciences Digital Quality & Compliance, and Chris Knackstedt, Managing Director of Cyber and Strategic Risk Practice at Deloitte & Touche, discuss the major challenges to AI adoption, highlighting governance, ethics, and compliance as top concerns. They emphasize the importance of integrating AI governance into existing risk management frameworks and navigating regulatory uncertainty, talent gaps, and ethical usage policies. The conversation also explores risks posed by AI agents, such as runaway behavior, misaligned learning, and context untraceability, stressing the need for human oversight and robust behavioral evaluations. Looking ahead, Michael anticipates a rise in governance tech to manage evolving AI risks, while Chris encourages organizations to build on their cybersecurity foundation and maintain momentum in AI strategy. Tune in and learn how to navigate the complex landscape of AI risk management and secure adoption! Resources:  Connect and follow Mike Crowthers on LinkedIn. Connect and follow Chris Knackstedt on LinkedIn. Learn more about Deloitte on their LinkedIn and website. Subscribe to The Current, Deloitte Cyber's quick-read series. Read our life sciences and health care industry insights. Visit the Deloitte AI Institute™ website. Explore The State of Generative AI in the enterprise 2024 year-end report. 

Host Justin Barnes recorded live at HIMSS25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests.This week his guests are Joe Morrow, IT Director, Technology Services at OSF Healthcare, and Sandra Colner, Global GM/Sr. Director of Healthcare and Life Sciences at Dell Technologies. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Clay is an American inventor and serial entrepreneur who holds more than 250 patents worldwide and is the Founder and Chairman of Ember, a global consumer electronics and life sciences brand best known for the Ember Mug, Ember Baby Bottle, and Ember Cube, all three of which independently have been named TIME Magazine's Best Inventions of the year. Ember was also recently named one of TIME Magazine's 100 Most Influential Companies in the world. Top 3 Value Bombs 1. Founder's gut can be a very powerful thing. 2. The team is the No. 1 factor. Putting together an incredible powerhouse team is key. 3. Inch by inch life's a cinch. Buy the yard, life's hard. Take one bite at a time and keep chugging it forward. Check out Clay's patented technology temperature control mugs and other products - Ember Sponsors The Speaker Lab - Want to learn how to get booked and paid to speak. Go to EOFire.com/speaker to grab your spot for our LIVE training on May 28th, and learn how to get booked and paid to speak. ThriveTime Show - Become the next success story, schedule a free consultation and request tickets to join Football Star, Tim Tebow and President Trump's Son, Eric Trump at Clay Clark's next business conference today at - ThrivetimeShow.com/eofire.